Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Western Union Co — how do they compare? Vertex Pharmaceuticals Incorporated trades at $520 (market cap $134.06B), while Western Union Co trades at $6.95 (market cap $2.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 62.1× Western Union Co's market cap, and Western Union Co pays a 13.54% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WU | |
|---|---|---|
Market Cap | $134.06B | $2.16B |
Sector | Health | Technology |
52-Week High | $557.96 | $10.28 |
52-Week Low | $376.62 | $6.36 |
Enterprise Value | $128.18B | $2.07B |
Dividend Yield | — | 13.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Western Union (WU) trades at $7.00, down 2.51% recently, with a bearish technical signal and neutral oscillators. Key financials show a P/E of 5.65 and net income margin of 9.79%, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. Recent news highlights a $200M cost-cutting plan and the pending Intermex acquisition, which faces regulatory hurdles. Analyst consensus is mixed, with a $7.14 price target and a 'Strong Sell' rating from some firms.
The outlook for WU is cautious due to declining revenue, integration risks from acquisitions, and competitive pressures. Opportunities include potential savings from efficiency initiatives and dividend yield appeal, but risks like margin pressure and regulatory delays could hinder recovery. Investors should weigh cost-cutting benefits against fundamental weaknesses in the money transfer sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
